Public blog
December 2018 By Sanjay Agrawal, Consultant Respiratory Intensivist As specialists with an interest in thoracic oncology, we want our patients to have the best outcome whether that’s as a result of screening, early diagnosis, surgery, radiotherapy, chemotherapy or … Read More
November 2018 By Fiona McDonald, Consultant Thoracic Clinical Oncologist The plenary session at WCLC 2018 in Toronto and parallel NEJM publication bring us the eagerly awaited overall survival results from the PACIFIC trial (NCT02125461). This was a randomised double-blind … Read More
October 2018 By James Spicer, Professor of Experimental Cancer Medicine and Consultant in Medical Oncology ALTA1: brigatinib vs crizotinib in ALK-rearranged non-small cell lung cancer The initial results of this comparison of brigatinib with the first generation drug crizotinib were presented … Read More
September 2018 By Dr Matthew Callister, Consultant Respiratory Physician CT screening in Europe took a leap forward this week with the publication of the mortality results from the NELSON screening study. NELSON was a population-based controlled trial that ran in the … Read More
August 2018 By Tom Newsom-Davis, Consultant Oncologist On 26th July 2018 one of the European Medicines Agency (EMA) committees recommended that the immunotherapy drug, Durvalumab, be licensed for use in patients with locally advanced (stage III) lung cancer. Although this does not mean … Read More
July 2018 By Tom Newsom-Davis, Consultant Oncologist NICE has just approved Alectinib as first line treatment for ALK-translocated NSCLC. https://www.nice.org.uk/guidance/gid-ta10206/documents/final-appraisal-determination-document This is exciting news for patients with this comparatively rare type of lung cancer. Currently the standard of care in the … Read More